No more bids for Par Pharma, so $1.9B deal with TPG stands

The auctioneer's gavel has come down for Par Pharmaceuticals ($PRX). The generics maker, with a $1.9 billion offer from TPG Capital in hand, had solicited competing bids--but none of the tire-kickers came through.

More than 40 potential bidders stepped forward during the go-shop period after Par and TPG came to terms. Three were serious enough to sign confidentiality agreements. But in the end, none made a formal bid.

So, the Texas-based private equity group will get Par for $50 per share, provided shareholders vote in favor at a special meeting next month.

Among those shareholders, of course, is Relational Investors, led by activist shareholder Ralph Whitworth. The group started agitating for a sale earlier this year, and as Dow Jones reports, met with Par officials in April. Whitworth figured that Par needed to join a consolidation wave in the generics business. Par had already snapped up some smaller rivals--including Anchen Pharmaceuticals, in a $410 million deal last year. But apparently that wasn't big enough for Whitworth.

- read the Dow Jones piece

Related Articles:
Par could fetch up to $2.5B from rival genericsmaker
Under pressure, Par agrees to $1.9B private equity buyout
Activist investor presses Par Pharma to sell itself
Par inks $410M deal for niche generics maker Anchen

Like what you're reading
Click here toget more news delivered to your inbox every day>>

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.